Aerpio Pharmaceuticals, Inc. (ARPO): Price and Financial Metrics
ARPO Price/Volume Stats
| Current price | $33.00 | 52-week high | $34.50 |
| Prev. close | $2.22 | 52-week low | $0.95 |
| Day low | $32.40 | Volume | 55,066 |
| Day high | $34.50 | Avg. volume | 5,147,753 |
| 50-day MA | $2.04 | Dividend yield | N/A |
| 200-day MA | $1.64 | Market Cap | 1.57B |
ARPO Stock Price Chart Interactive Chart >
Aerpio Pharmaceuticals, Inc. (ARPO) Company Bio
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is based in Cincinnati, Ohio
Latest ARPO News From Around the Web
Below are the latest news stories about Aerpio Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARPO as an investment opportunity.
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private PlacementLOS ANGELES, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the closing of its previously announced merger with Aerpio Pharmaceuticals, Inc. (previously traded on the Nasdaq Capital Market under ARPO). |
Earnings Report: Heres what to expect from Aerpio Pharmaceuticals (NASDAQ:ARPO)Earnings results for Aerpio Pharmaceuticals , Analyst Opinion on Aerpio Pharmaceuticals , Earnings and Valuation of (NASDAQ:ARPO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Earnings Report: Heres what to expect from Aerpio Pharmaceuticals (NASDAQ:ARPO) appeared first on . |
Aerpio Reports Second Quarter 2021 Financial Results and Provides Business UpdateCINCINNATI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Aerpio) (Nasdaq: ARPO), a biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2021 and provided a business update. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back, trader! |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
ARPO Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 11.68% |
| 5-year | -29.49% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 57.18% |
| 2019 | -63.32% |
Continue Researching ARPO
Here are a few links from around the web to help you further your research on Aerpio Pharmaceuticals Inc's stock as an investment opportunity:Aerpio Pharmaceuticals Inc (ARPO) Stock Price | Nasdaq
Aerpio Pharmaceuticals Inc (ARPO) Stock Quote, History and News - Yahoo Finance
Aerpio Pharmaceuticals Inc (ARPO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...